Anika Therapeutics, Inc. (ANIK)

Good entry point.

Strong pipeline/partnerships/mgt. Beaten down by econ fears. Hold until it outperforms the market by thirty percent or so. PE when added was 20.2

Testing out a portfolio of smallish-cap 5-star stocks found using the CAPS screener. All picks have at least 50 allstars backing them, which should be enough to minimize star rating fluctuations. It's been less than a week, but so far so good!

Testing a portfolio of companies that start with the letter "A".

sounds cool

Extremely low Enterprise value. Growing and accelerating earnings. Unfairly punished

Great
value at this price.

Anika has a very low market cap given the number and variety of products it is already marketing. Quarterly revenues have substantial potential for growth given planned launch of Monovisc in Europe this quarter and possible new marketing deal for Elevess this year. They have also made progress in their pipeline, recently initiating a pivotal US trial for Monovisc. All the recent news has been good, but the stock price has been dipping. There is almost no short interest and a reasonable financial bottom line, so it's hard to see any justification for the recent decline. 13 may not be the bottom, but it seems like a pretty nice entry point.

From Motley Fool hard to meet screen.

Elevess and host of future related products, marketed by Galderma will provide growth for multiple years. Already profitable and no debt.

Relatively unknown:"BEST Vanity and Youth Play" thru FDA approved hyloranian acid for orthoritis of knee and removal of aging facial lines. Tripling pdtn facility for future growth. Place limit orders: thin stock.

he Company develops, manufactures and commercializes therapeutic products for tissue protection and healing

New products second half. P/E looks high. Any room to make some money?

This year's earnings trade at a 29 p/e for .51 est. With a ttm p/e of 36. So lets say they hit the numbers and get .51. That should imply an $18 stock based on the ttm p/e of 36. It woud seem 36 is pretty high and I would bet the TTM goes down more than up. So 20% upside doesn't give much room for comfort if we look at backwards p/e.

New things are coming so maybe forward p/e is the better metric. Say they hit .51 and the following years est. is .79 according to the analysts right now. Based on the current forward p/e of 29 (off of the .51 est) gets you a $22 stock on .79 after they hit the .51 numbers. So there you have it - this stock should trade between 18 and 22 by the end of the fiscal year. More likely 22. That's assuming the new products will really generate the growth that this p/e imply.

For the risk assumed about the new products, investors can expect a tiddy 46% profit if it paysoff.

ANIK has the "gorilla" marketing partner, JNJ (Johnson and Johnson)to make it very successful for strong deployment of "orthovisc" throughout U.S. and international. "Elevess", new product just now being deployed with Galderma, should begin to take hold for 3rd quarter. New products, higher sales, should equate to much higher eps and stock price. Technically excellent formations for accumulation ongoing makes ANIK very attractive.

Good products, reasonable PE.

Earnings are great, they have received approvals for new drugs and the US sales of their new orthopedic treatment is expected to be very strong.

approval of comestic filler for use in Europe should add to revenue ... been watching it a while just wished I'd bought it earlier

it's a major growth sector

Anik has a derma filler with low risk